tirzepatide type 1 diabetes trial 🚨 in – TIRTLE-1 @EASD 2025 🚨 🔹 First RCT evidence – though small, adds weight to earlier real-world observations. 🔹 Demonstrates improvements in: ✓ Weight ✓ SURPASS-CVOT Published: Large Trial Confirms

One of its main advantages is that it has a long duration, so in most cases a once-a-week injection suffices

A clear example of the category is repair and recovery peptides such as GHK-Cu, a copper peptide known for signaling skin and tissue to support healing, firmness, and renewal

The ability to burn fat: An increase in muscle mass boosts the bodys resting metabolic rate leading to more calories being burned throughout the day

Semaglutide is specifically formulated and dosed for once-weekly injection only

Each needle entry into a compounded vial introduces potential bacterial exposure

What makes this approval particularly significant is that Zepbound addresses both the weight management and sleep apnea simultaneously, tackling the root cause while directly treating the condition